Publications by authors named "P Glue"
Background: Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic and antidepressant properties.
Aims: To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD.
Fibromyalgia is a chronic pain condition contributing to significant disability worldwide. Neuroimaging studies identify abnormal effective connectivity between cortical areas responsible for descending pain modulation (pregenual anterior cingulate cortex, pgACC) and sensory components of pain experience (primary somatosensory cortex, S1). Neurofeedback, a brain-computer interface technique, can normalise dysfunctional brain activity, thereby improving pain and function.
View Article and Find Full Text PDFPurpose: Anxiety disorders are a major global issue. Diagnosis via symptoms, not biological causes, delivers poor treatment outcomes. Our frontal EEG biomarker, Goal Conflict Specific Rhythmicity (GCSR; 4-12 Hz), developed from our long-standing detailed neuropsychological theory of anxiety processes, is reduced by all chemical types of selective anxiolytic and is high in cases across a range of currently diagnosed anxiety disorders.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the effects of intramuscular (IM) ketamine on treatment-resistant Obsessive-Compulsive Disorder (OCD), comparing it to IM fentanyl.
- The results showed that ketamine significantly reduced OCD symptoms, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), especially at higher doses.
- Although ketamine was associated with short-term dissociative effects, this research provides promising evidence for its use in managing severe OCD, suggesting that further studies are needed for optimal dosing and long-term effects.